500124 logo

Dr. Reddy's Laboratories Limited Stock Price

BSE:500124 Community·₹1.0t Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 28 Fair Values set on narratives written by author

500124 Share Price Performance

₹1,198.45
-89.75 (-6.97%)
₹1,625.93
Fair Value
₹1,198.45
-89.75 (-6.97%)
27.8% undervalued intrinsic discount
₹1,660.00
Fair Value
Price ₹1,198.45
AnalystHighTarget ₹1,660.00
AnalystConsensusTarget ₹1,300.62
AnalystLowTarget ₹990.00

500124 Community Narratives

AnalystHighTarget·
Fair Value ₹1.63k 26.3% undervalued intrinsic discount

Global Aging Trends Will Expand Biosimilars And Generics Markets

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystConsensusTarget·
Fair Value ₹1.3k 7.9% undervalued intrinsic discount

Biosimilar Expansion And Legal Agreements Will Shape Future Market Opportunities

0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
AnalystLowTarget·
Fair Value ₹990 21.1% overvalued intrinsic discount

Intensifying Pricing Pressures And Regulatory Crackdowns Will Erode Future Profitability

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
₹1.3k
7.9% undervalued intrinsic discount
Revenue growth
4.62% p.a.
Profit Margin
15.59%
Future PE
25.32x
Share price in 2028
₹1.86k
₹990
21.1% overvalued intrinsic discount
AnalystLowTarget Fair Value
Revenue growth
2.33% p.a.
Profit Margin
11.11%
Future PE
29.58x
Share price in 2028
₹1.42k

Snowflake Analysis

Flawless balance sheet established dividend payer.

1 Risk
4 Rewards

Dr. Reddy's Laboratories Limited Key Details

₹342.1b

Revenue

₹149.1b

Cost of Revenue

₹193.1b

Gross Profit

₹134.5b

Other Expenses

₹58.6b

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
70.41
56.43%
17.13%
12.4%
View Full Analysis

About 500124

Founded
1984
Employees
27811
CEO
Erez Israeli
WebsiteView website
www.drreddys.com

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; and research and development of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Recent 500124 News & Updates

Recent updates

No updates